Genes & Development · 2016 · 109 citations · 32 references
Life SciencesMolecular BiologyOncologyApoptosisMolecular OncologyTranscriptional RegulationCancer Cell SignalingCholesterol BiosynthesisCholesterol MetabolismLipid MetabolismLiver DiseaseOncogenic Signaling PathwaysCellular Cholesterol HomeostasisCholesterol AccumulationCholesterol Depletion EffectsDietary CholesterolHepatocellular Carcinoma PathogenesisHippo SignalingHippo Signaling PathwayOrgan Size Control
The Hippo signaling pathway is a major regulator of organ size. In the liver, Hippo pathway deregulation promotes hyperplasia and hepatocellular carcinoma primarily through hyperactivation of its downstream effector, YAP. The LATS2 tumor suppressor is a core member of the Hippo pathway. A screen for LATS2-interacting proteins in liver-derived cells identified the transcription factor SREBP2, master regulator of cholesterol homeostasis. LATS2 down-regulation caused SREBP activation and accumulation of excessive cholesterol. Likewise, mice harboring liver-specific Lats2 conditional knockout (Lats2-CKO) displayed constitutive SREBP activation and overexpressed SREBP target genes and developed spontaneous fatty liver disease. Interestingly, the impact of LATS2 depletion on SREBP-mediated transcription was clearly distinct from that of YAP overexpression. When challenged with excess dietary cholesterol, Lats2-CKO mice manifested more severe liver damage than wild-type mice. Surprisingly, apoptosis, inflammation, and fibrosis were actually attenuated relative to wild-type mice, in association with impaired p53 activation. Subsequently, Lats2-CKO mice failed to recover effectively from cholesterol-induced damage upon return to a normal diet. Additionally, decreased LATS2 mRNA in association with increased SREBP target gene expression was observed in a subset of human nonalcoholic fatty liver disease cases. Together, these findings further highlight the tight links between tumor suppressors and metabolic homeostasis.
32
Role of YAP/TAZ in mechanotransduction
Sirio Dupont, Leonardo Morsut, Mariaceleste Aragona et al. · Nature · 2011 · 5.9K citations · Full text
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15
Jay D. Horton, Nila Shah, Janet A. Warrington et al. · Proceedings of the National Academy of Sciences · 2003 · 1.4K citations · Full text